Kinase inhibitors

A compound of the formula:

• or pharmaceutically acceptable salts, crystal forms or diastereomers thereof, wherein:
• D is:
• where X1, X2, X3, X4 are optionally substituted carbon, or one of X1, X2, X3, X4 is N;
• R2 is 0-4 substituents independently chosen from H, halogen, C1-4 alkyl, CH2F, CHF2, CF3, OCF3, aryl, hetaryl, C1-4 alkylOC1-4 alkyl, C1-4 alkylOaryl, C1-4 alkylNR3R4, CO2R3, CONR3R4, CONR3SO2R4, NR3R4, C1-4 alkylNR3R4, nitro, NR3COR4, NR5CONR3R4, NR3SO2R4, C1-4 alkylNR3COR4, C1-4 alkylNR5CONR3R4, or C1-4 alkylNR3SO2R4;
• R3 and R4 are each independently H, halogen, CH2F, CHF2, CF3, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 cyclohetalkyl, aryl, C1-4 alkyl aryl, hetaryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered (saturated or unsaturated) ring optionally containing an atom selected from O, S, NR6;
• R5 is H, C1-4 alkyl, halogen, CH2F, CHF2, CF3, aryl or hetaryl;
• R6 is H, C1-4 alkyl, aryl, hetaryl, C1-4 alkyl aryl, or C1-4 alkyl hetaryl;
• R1 is H, C1-4 alkyl, C1-6 cycloalkyl;
• Q is a bond, CH2, C1-4 alkyl;
• A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, OCF3, CN, NR8R9, aryl, hetaryl, C1-4 aryl, C1-4 hetaryl, C1-4 alkylNR8R9, OC1-4 alkylNR8R9, nitro, NR10C1-4NR8R9, NR8COR9, NR10CONR8R9, NR8SO2R9, CONR8R9, or CO2R8, where R8 and R9 are each independently H, C1-4 alkyl, aryl or which together form an optionally substituted 4-8 membered ring which may contain a heteroatom selected from O, S, NR11, where R11 is C1-4 alkyl, and R10 is selected from H, C1-4 alkyl;
• and
• W is H, C1-4 alkyl, or C2-6 alkenyl, where C1-4 alkyl or C2-6 alkenyl may be optionally substituted with C1-4 alkyl, OH, OC1-4 alkyl, NR12R13;
• and R12, and R13 are each independently H, C1-4 alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, and NR14 where R14 is H or C1-4 alkyl.